Auro Laboratories Limited has submitted the Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for Resignation of Mr. Kuntal Pancholi as the Chief Financial Officer & Key Managerial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mr. Kuntal Pancholi has resigned as Chief Financial Officer and Key Managerial Personnel of Auro Laboratories Ltd with immediate effect from May 28, 2026. The resignation is attributed to personal reasons, and the company has confirmed there is no other material reason behind the departure. The exit leaves a senior finance leadership position vacant at the company. No replacement has been announced yet. The resignation letter has been submitted to BSE as required under SEBI LODR regulations.
The CFO vacancy creates a leadership gap in the company's finance function. Investors should watch for an appointment announcement. The explicit confirmation that no material reasons prompted the resignation is a positive indicator, suggesting no underlying governance or financial concerns.